ACAA2 (acetyl-CoA acyltransferase 2) is a mitochondrial enzyme that catalyzes the final step of fatty acid β-oxidation, cleaving medium- to long-chain 3-oxoacyl-CoAs into acetyl-CoA and shortened fatty acyl-CoA molecules 1. The enzyme plays a critical role in energy metabolism by facilitating fatty acid oxidation, particularly during metabolic stress conditions 2. ACAA2 expression is regulated by transcription factors including KLF15 and PPARα, and its loss contributes to metabolic dysfunction in kidney injury models 1. The protein undergoes post-translational modifications including palmitoylation, which governs its subcellular localization and function in hepatic stellate cells 3. In disease contexts, ACAA2 shows complex roles: it acts as a tumor suppressor in renal cell carcinoma with higher expression associated with better prognosis and enhanced immune infiltration 4, while serving as an oncogene in ovarian cancer where it promotes malignant progression 5. ACAA2 is elevated in small-cell neuroendocrine cancers, making it a potential diagnostic marker 6. Additionally, ACAA2 demonstrates protective effects against liver fibrosis through regulation of hepatic stellate cell ferroptosis, and shows divergent expression patterns between cancer and neurodegenerative diseases, suggesting its role as a metabolic mediator in disease crosstalk 7.